Summary of COVID-19 antroquinonol studies

1. Cheng et al., A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19

124 patient antroquinonol late treatment RCT: 200% higher progression (p=1), 17% slower recovery (p=0.72), 2% shorter hospitalization (p=0.92), and 7% faster viral clearance (p=0.87).
RCT 124 hospitalized COVID-19 patients showing no significant differences with antroquinonol.
Dec 2021, NCT04523181, https://clinicaltrials.gov/study/NCT04523181, https://c19p.org/cheng7